Zimmer Biomet (ZBH) traded lower (down about 3% to $89.83) as the market turned cautious into the company’s upcoming first-quarter 2026 earnings report on April 28, 2026. With the print days away, investors appeared to reduce exposure amid a still-choppy backdrop for large-cap orthopedics and heightened sensitivity to any signs of market-share pressure or margin giveback.

Sell-side commentary in recent weeks has skewed more cautious, with downgrades highlighting slower organic growth and fewer near-term catalysts. That tone has left ZBH more vulnerable to pre-earnings de-risking, especially after a multi-quarter period in which investors have been debating whether new product cycles and commercial execution can meaningfully re-accelerate growth versus peers.

Key swing factors for the April 28 report include procedure-volume trends, pricing and competitive dynamics in hips and knees, and whether management reiterates full-year expectations. Investors will also focus on margin drivers—particularly any incremental pressure tied to tariffs, product mix, and integration/dilution effects from Paragon 28—as well as any timeline updates for longer-dated technology catalysts that could influence sentiment beyond 2026.